Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hepatitis C]

A Gattoni1, A Cecere, R Caiazzo

  • 1II Università degli Studi di Napoli, Dipartimento di Internistica Clinica e Sperimentale F. Magrassi.

La Clinica Terapeutica
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Platelet number is negatively and independently associated with carotid intima-media thickness in apparently healthy overweight/obese subjects.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2018
Same author

Site and type of craniopharyngiomas impact differently on 24-hour circadian rhythms and surgical outcome. A neurophysiological evaluation.

Autonomic neuroscience : basic & clinical·2017
Same author

A new integrated instrumental approach to autonomic nervous system assessment.

Computer methods and programs in biomedicine·2014
Same author

Switching on the deep brain stimulation: effects on cardiovascular regulation and respiration.

Autonomic neuroscience : basic & clinical·2011
Same author

Dermatosis related to rheumatic infection; Pathogenesis of lupus erythematosus and the test of Mester.

Il Progresso medico·2010
Same author

The use of IFN-alpha in subjects with liver transplant for hepatitis C.

Panminerva medica·2009
Same journal

Effectiveness of Focal Muscle Vibration in Post-Anterior Cruciate Ligament Reconstruction Rehabilitation: A Case Report.

La Clinica terapeutica·2026
Same journal

Violence Against Women as a Public-Health Exposure: Biological Embedding, Medico-Legal Caution and Precision Prevention in the EpiWe Framework.

La Clinica terapeutica·2026
Same journal

Suicide of the Work-Disabled Individual Affected by Neoplasia with Unfavorable Prognosis: Evidence-Based Legal Medicine in Reconstructing the Causal Link.

La Clinica terapeutica·2026
Same journal

The therapeutic potential of N-acetylcysteine across multiple organ systems: a narrative review.

La Clinica terapeutica·2026
Same journal

Mesotherapy in Pain Management in Primary Care: A Narrative Review and Practice-Oriented Appraisal.

La Clinica terapeutica·2026
Same journal

Bone Marrow Edema in Rheumatic Diseases: Incidence, Diagnosis, and Therapeutic Implications. A Narrative Review.

La Clinica terapeutica·2026
See all related articles

Hepatitis C virus (HCV) causes chronic infection due to rapid mutation, leading to liver disease. Standardizing alpha-interferon (alpha-IFN) treatment aims to improve outcomes for HCV carriers.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) infects over 100 million people globally, with transmission routes often unclear.
  • HCV's high mutation rate generates quasi-species, enabling immune evasion and chronic infection.
  • Chronic infection can progress to cirrhosis and hepatocarcinoma, but disease severity varies significantly among patients.

Purpose of the Study:

  • To investigate the factors influencing the clinical course of chronic Hepatitis C virus infection.
  • To evaluate the efficacy of alpha-interferon (alpha-IFN) in managing chronic Hepatitis C.
  • To establish standardized treatment protocols for alpha-IFN therapy in HCV chronic hepatitis.

Main Methods:

  • Review of existing literature on HCV transmission, pathogenesis, and treatment.

Related Experiment Videos

  • Analysis of clinical data regarding disease progression and patient outcomes.
  • Evaluation of alpha-interferon (alpha-IFN) efficacy and treatment parameters.

    • Main Results:

    • HCV quasi-species contribute to immune escape and disease persistence.
    • Alpha-interferon (alpha-IFN) is the primary treatment, though eradication rates are low.
    • Significant variability exists in disease progression, from mild to aggressive forms.

    Conclusions:

    • Understanding HCV quasi-species and immune evasion is crucial for developing effective therapies.
    • Standardizing alpha-interferon (alpha-IFN) dosage and duration is necessary to optimize treatment outcomes.
    • Further research is needed to address the variability in clinical presentation and improve HCV management.